On the pivotal role of drug discovery in sustainable EU pharma reform

Bart De Spiegeleer; Benoit Deprez; Eelko Hak; Michal Markuszewski; Evelien Wynendaele

doi:10.1016/j.drudis.2024.104097

On the pivotal role of drug discovery in sustainable EU pharma reform

Bart De Spiegeleer, Benoit Deprez, Eelko Hak, Michal Markuszewski, Evelien Wynendaele^*

^*Corresponding author voor dit werk

Onderzoeksoutput: Editorial › Academic › peer review

2 Citaten (Scopus)

31 Downloads (Pure)

Samenvatting

The proposed EU pharma reform adds the ERA as a mandatory fourth approval criterion.

A global evaluation of drug sustainability throughout the full life cycle is needed.

The early discovery phase is pivotal for the environmental impact of a medicine.

The evaluation of drug sustainability should involve all relevant stakeholders.

Originele taal-2	English
Artikelnummer	104097
Aantal pagina's	3
Tijdschrift	Drug Discovery Today
Volume	29
Nummer van het tijdschrift	10
DOI's	https://doi.org/10.1016/j.drudis.2024.104097
Status	Published - okt.-2024

Toegang tot document

10.1016/j.drudis.2024.104097

On the pivotal role of drug discovery in sustainable EU pharma reformFinal publisher's version, 329 KBLicentie: Taverne

Handle.net

Permanente koppeling

Andere bestanden en links

Link naar publicatie in Scopus

Citeer dit

@article{9e86f690630847cf97090d30c71d5b40,

title = "On the pivotal role of drug discovery in sustainable EU pharma reform",

abstract = "The proposed EU pharma reform adds the ERA as a mandatory fourth approval criterion.A global evaluation of drug sustainability throughout the full life cycle is needed.The early discovery phase is pivotal for the environmental impact of a medicine.The evaluation of drug sustainability should involve all relevant stakeholders.",

author = "{De Spiegeleer}, Bart and Benoit Deprez and Eelko Hak and Michal Markuszewski and Evelien Wynendaele",

year = "2024",

month = oct,

doi = "10.1016/j.drudis.2024.104097",

language = "English",

volume = "29",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "ELSEVIER SCI LTD",

number = "10",

}

TY - JOUR

T1 - On the pivotal role of drug discovery in sustainable EU pharma reform

AU - De Spiegeleer, Bart

AU - Deprez, Benoit

AU - Hak, Eelko

AU - Markuszewski, Michal

AU - Wynendaele, Evelien

PY - 2024/10

Y1 - 2024/10

N2 - The proposed EU pharma reform adds the ERA as a mandatory fourth approval criterion.A global evaluation of drug sustainability throughout the full life cycle is needed.The early discovery phase is pivotal for the environmental impact of a medicine.The evaluation of drug sustainability should involve all relevant stakeholders.

AB - The proposed EU pharma reform adds the ERA as a mandatory fourth approval criterion.A global evaluation of drug sustainability throughout the full life cycle is needed.The early discovery phase is pivotal for the environmental impact of a medicine.The evaluation of drug sustainability should involve all relevant stakeholders.

UR - http://www.scopus.com/inward/record.url?scp=85199065220&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2024.104097

DO - 10.1016/j.drudis.2024.104097

M3 - Editorial

C2 - 38992421

AN - SCOPUS:85199065220

SN - 1359-6446

VL - 29

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 10

M1 - 104097

ER -

On the pivotal role of drug discovery in sustainable EU pharma reform

Samenvatting

Toegang tot document

Handle.net

Andere bestanden en links

Vingerafdruk

Citeer dit